Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb and 360Dx.
Labs and commercial developers have created simple, inexpensive PCR assays for the SARS-CoV-2 Delta variant that they say could help surveillance efforts.
The firm is investing its COVID testing revenues to expand its oncology offerings through acquisitions and partnerships.
The assay detects mutations associated with the Alpha variant, and the team expects to make a Delta variant test publicly available within the week.
A home-collected dry swab protocol showed 100 percent sensitivity and 99.4 percent specificity versus extraction-based RT-qPCR.
The new guidelines include recommendations for molecular testing in suspected cases of Mycoplasma genitalium and bacterial vaginosis.
Clear Labs has developed a SARS-CoV-2 variant monitoring engine for clinical samples and recently presented pilot data for wastewater surveillance.
New federal funding support and technological approaches are enlivening wastewater pathogen testing in the US, attracting developers and lab programs.
The tool combines geographical data on viral mutations with an easy-to-use interface to check whether primers may be affected.
The Hopkins team expects to spinout a company soon in order to commercialize the technology in the next two to three years.
The firm expects to soon carve out a share in the rapidly expanding point-of-care, infectious disease, molecular diagnostics market.